|
|
|
Drug Deal
Achillion teams with Canadian firm for drug discovery
|
Business New Haven
4/28/2003
By: BNH
|
Achillion Pharmaceutical and Phytobiotech have signed a partnership agreement to discover infectious disease targets.. According to the terms of the pact, Phytobiotech will supply Achillion with purified, plant-supplied small molecules that Achillion will screen through infectious disease-target assays.
“Compound libraries of natural products offer a rich source of chemical diversity, but often the pharmaceutically interesting compounds are difficult to separate from the mixture,” explains Milind Deshpande, Achillion's vice president of drug discovery.
“Phytobiotech has addressed this dilemma by creating unique small molecules assembled from plant cell cultures that are compatible with high-throughput drug-discovery processes,” he says.
“From this collaboration we are able to exploit our infectious disease targets to screen for potential clinical candidates from an increasingly diverse chemical library.”
Based in Laval, Quebec, Phytobiotech is a private company focused of drugs to treat and cancer and other infectious diseases.
According to Achillion's senior director of business development, Kevin Eastwood: “This collaboration capitalizes on the resources of both organizations to identify novel chemotypes derived from plats for the treatment of serious infectious diseases, leveraging both Phytobiotech's novel chemical diversity and Achillion's drug discovery and clinical development expertise.”
Adds Phytobiotech vice president of corporate development Richard Gauthier, “Achillion's leading anti-viral and anti-bacterial drug-discovery capabilities have identified key therapeutic targets we are eager to explore using our PurePhytoLib. Coupled with Achillion's experienced drug-development team, pre-clinical discoveries can advance rapidly and efficiently into proof-of-principle human clinical studies.”
|
Go FirstGo PreviousGo
NextGo LastGo
to Index
|
|
